Stock Scorecard
Stock Summary for Kala Pharmaceuticals Inc (KALA) - $6.71 as of 5/9/2024 11:12:20 PM EST
Total Score
11 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for KALA
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for KALA
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for KALA
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for KALA
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for KALA
Financial Details for KALA
Company Overview |
|
|---|---|
| Ticker | KALA |
| Company Name | Kala Pharmaceuticals Inc |
| Country | USA |
| Description | Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of therapies using its proprietary nanoparticle-based mucus penetrating particle (MPP) technology for the treatment of eye diseases. The company is headquartered in Watertown, Massachusetts. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 8/2/2024 |
Stock Price History |
|
| Last Day Price | 6.71 |
| Last Day Price Updated | 5/9/2024 11:12:20 PM EST |
| Last Day Volume | 712 |
| Average Daily Volume | 10,900 |
| 52-Week High | 19.35 |
| 52-Week Low | 5.10 |
| Last Price to 52 Week Low | 31.57% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 114.24 |
| Sector PE | 93.69 |
| 5-Year Average PE | -1.12 |
| Free Cash Flow Ratio | 0.37 |
| Industry Free Cash Flow Ratio | 14.44 |
| Sector Free Cash Flow Ratio | 32.94 |
| Current Ratio Most Recent Quarter | 6.33 |
| Total Cash Per Share | 18.07 |
| Book Value Per Share Most Recent Quarter | 2.72 |
| Price to Book Ratio | 2.70 |
| Industry Price to Book Ratio | 6.21 |
| Sector Price to Book Ratio | 22.04 |
| Price to Sales Ratio Twelve Trailing Months | 1.16 |
| Industry Price to Sales Ratio Twelve Trailing Months | 17.08 |
| Sector Price to Sales Ratio Twelve Trailing Months | 7.83 |
Share Statistics |
|
| Total Shares Outstanding | 2,816,400 |
| Market Capitalization | 18,898,044 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 5.85% |
| Reported EPS 12 Trailing Months | -17.35 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | -17.94 |
| Net Income Twelve Trailing Months | -42,199,000 |
| Net Income Past Year | -42,199,000 |
| Net Income Prior Year | -44,822,000 |
| Quarterly Revenue Growth YOY | -100.00% |
| 5-Year Revenue Growth | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 50,895,000 |
| Total Cash Past Year | 50,895,000 |
| Total Cash Prior Year | 70,495,000 |
| Net Cash Position Most Recent Quarter | 16,705,000 |
| Net Cash Position Past Year | 16,705,000 |
| Long Term Debt Past Year | 34,190,000 |
| Long Term Debt Prior Year | 43,303,000 |
| Total Debt Most Recent Quarter | 34,190,000 |
| Equity to Debt Ratio Past Year | 0.18 |
| Equity to Debt Ratio Most Recent Quarter | 0.18 |
| Total Stockholder Equity Past Year | 7,504,000 |
| Total Stockholder Equity Prior Year | 18,974,000 |
| Total Stockholder Equity Most Recent Quarter | 7,504,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.12 |
| MACD Signal | -0.19 |
| 20-Day Bollinger Lower Band | 6.35 |
| 20-Day Bollinger Middle Band | 7.24 |
| 20-Day Bollinger Upper Band | 8.13 |
| Beta | -1.75 |
| RSI | 49.05 |
| 50-Day SMA | 9.59 |
| 200-Day SMA | 127.44 |
System |
|
| Modified | 5/9/2024 11:12:23 PM EST |